GEMP Gemphire Therapeutics Inc.

0.53
0  -0%
Previous Close 0.53
Open 0.53
Price To Book 4.08
Market Cap 7,882,378
Shares 14,872,411
Volume 66,747
Short Ratio
Av. Daily Volume 279,066

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial terminated - noted August 10, 2018.
Gemcabene
Pediatric Non-Alcoholic Fatty Liver Disease (NAFLD)
Phase 2b primary endpoint met - June 28, 2018.
Gemcabene - INDIGO-1
Severe Hypertriglyceridemia (SHTG)
Phase 2b data released August 7, 2017 - primary endpoint met but lower than expectations.
Gemcabene - ROYAL-1
Heterozygous Familial Hypercholesterolemia (HeFH)
Phase 2b data released June 28, 2017 - primary endpoint met.
Gemcabene - COBALT-1
Homozygous Familial Hypercholesterolemia (HoFH)
Phase 2 top-line released June 26, 2019.
Gemcabene
Familial Partial Lipodystrophy (FPL)